Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
129 Results for "
complication
" in MedChemExpress (MCE) Product Catalog:
Products (129)
129 Results for "complication" in MCE Product Catalog:
Cat. No.: HY-N11875S
Cat. No.: HY-107207R
CAS No.: 32602-81-6
Synonyms: Kaempferol 3-O-neohesperidoside (Standard)
Target:
Cat. No.: HY-125863C
CAS No.: 9001-40-5
Synonyms: G6PD, Bacillus sp.
Target:
Research Areas:
Glucose-6-phosphate dehydrogenase, Bacillus sp. (G6PD, Bacillus sp.) (EC 1.1.1.49) is an NADP-dependent antioxidant metabolic enzyme. Glucose-6-phosphate dehydrogenase, Bacillus sp. is induced by sublethal doses of Menadione (HY-B0332) and increasing concentrations of NaCl in Bacillus sp. F26. Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the oxidation of glucose-6-phosphate (G6P) to 6-phosphoglucono-δ-lactone, while reducing NADP + to NADPH, providing reducing power for the antioxidant defense system and cellular redox balance of Bacillus sp. F26. Glucose-6-phosphate dehydrogenase, Bacillus sp. is used in research related to diabetic complications .
Cat. No.: HY-L127
39 compounds
Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. The orthopoxvirus genus consists of 12 viruses including variola virus, vaccinia virus (VV), cowpox viruses (CV), monkeypox virus, and camelpox virus. Smallpox has been eradicated worldwide in 1980, but some other orthopoxvirus, such as monkeypox virus, are still threats to human health.
There are not many drugs available for orthopoxvirus treatment. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG). In 2021, brincidofovir was approved by FDA for the treatment of smallpox and tecovirimat was approved by EMA for the treatment of monkeypox in 2022. A few active compounds including interferon and interferon inducers, and a variety of nucleosides or nucleotides have been reported to have activity against orthopoxvirus.
MCE carefully prepared a unique collection of 39 compounds reported with the anti- orthopoxvirus activity which can be used for drug screening and other research about orthopoxvirus.
Cat. No.: HY-P1615
CAS No.: 1006388-38-0
Synonyms: UPARANT
Cat. No.: HY-N16527
CAS No.: 233690-85-2
Cat. No.: HY-175862
CAS No.: 2135481-84-2
Target:
Free Radical Scavengers Aldose Reductase Reactive Oxygen Species (ROS) PI3K Akt SOD p38 MAPK Keap1-Nrf2
Research Areas:
ALR2-IN-9 is a potent ALR2 inhibitor (IC50 = 21.8 nM) with excellent antioxidant activity (EC50 for DPPH radical scavenging = 2.8 μM). ALR2-IN-9 interacts directly with Reactive Oxygen Species (ROS)/Reactive Nitrogen Species (RNS) and interrupts the free radical chain reactions, and as an endogenous enzymatic antioxidant regulator, which regulates enzyme functions of CAT and SOD. ALR2-IN-9 regulates PI3K/Akt/Nrf2 pathway to attenuate hyperglycemia-mediated mitochondrial superoxide overproduction in vitro, and ameliorates CuSO4- and H2O2-induced oxidative stress in vivo. ALR2-IN-9 prolongs lifespan of C. elegans via the regulation of stress response genes such as PMK-1. ALR2-IN-9 is a promising anti-aging drug candidate. ALR2-IN-9 can be used for diabetic complication research .
Cat. No.: HY-L073
394 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.
MCE offers a unique collection of 394 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
